Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4922MR)

This product GTTS-WQ4922MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4922MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2930MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ13539MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ2408MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ7322MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ12459MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12074MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ7595MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ465MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 3G3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW